BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 34361090)

  • 1. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma.
    Wu Q; Berglund AE; Etame AB
    Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T; Mingyi M; Qiu X; Qiu Y
    Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
    Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of metabolism in glioblastoma.
    Dong Z; Cui H
    Semin Cancer Biol; 2019 Aug; 57():45-51. PubMed ID: 30205139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma.
    Wu Q; Berglund AE; Wang D; MacAulay RJ; Mulé JJ; Etame AB
    Sci Rep; 2019 Oct; 9(1):14072. PubMed ID: 31575897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
    Wang J; Li T; Wang B
    Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34278448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
    Le Calvé B; Rynkowski M; Le Mercier M; Bruyère C; Lonez C; Gras T; Haibe-Kains B; Bontempi G; Decaestecker C; Ruysschaert JM; Kiss R; Lefranc F
    Neoplasia; 2010 Sep; 12(9):727-39. PubMed ID: 20824049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced modifications and modulations of microRNAs and long non-coding RNAs for future therapy against Glioblastoma Multiforme.
    Janaki Ramaiah M; Divyapriya K; Kartik Kumar S; Rajesh YBRD
    Gene; 2020 Jan; 723():144126. PubMed ID: 31589963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
    Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
    Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
    Uddin MS; Mamun AA; Alghamdi BS; Tewari D; Jeandet P; Sarwar MS; Ashraf GM
    Semin Cancer Biol; 2022 Aug; 83():100-120. PubMed ID: 33370605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the epigenetics of glioblastomas.
    Ferreira WA; Pinheiro Ddo R; Costa Junior CA; Rodrigues-Antunes S; Araújo MD; Leão Barros MB; Teixeira AC; Faro TA; Burbano RR; Oliveira EH; Harada ML; Borges Bdo N
    Epigenomics; 2016 Sep; 8(9):1289-305. PubMed ID: 27585647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
    Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
    J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
    Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.